Resumen

Objectives: To assess the safety and efficacy of a synergistic protocol for treating flaccidity, which is based on combining different products in order to to treat flaccidity in perimenopausal and postmenopausal women. Introduction: Facial ageing is a continuous and multifactorial process caused by different molecular and cell changes. The decrease in oestrogen levels during menopause plays a key role as it is linked to a decrease in transforming growth factor beta (TGF-β),1 the main activator of extracellular matrix proteins (collagen, elastin, HA, reticulin). mesohyal® redenx contains palmitoyl tripeptide-5, which activates TGF-β2 , helping to restore the endogenous cutaneous mechanism in perimenopausal and postmenopausal women. Materials / method: A clinical study was carried out between July and December 2023 involving 13 perimenopausal and postmenopausal patients divided into two groups based on the degree of ageing. The protocol aimed skin renewal with peels, cell biostimulation with mesotherapy, volume replacement with filler and homecare treatment to promote and maintain long-term results. It consisted of 1 session with 20/25 mg/ml cross-linked HA, 3 mesotherapy sessions (15 mg/ml free HA, palmitoyl tripeptide-5, acetyl tetrapeptide-9 and DMAE) and 3 peel sessions (18% lactic acid, 18% glycolic acid, 2% retin@l, 1% bakuchiol) for m Results: The clinical results of the two study groups demonstrate noticeable skin rejuvenation, with reduced pigmentation and improved skin quality. In addition, the replacement of the facial support structures provides structure and firmness to the skin, thereby correcting facial sagging. Ex vivo data demonstrated an increase in TGF-β on kin explants treated with biomimetic peptides and analysed using immunofluorescence microscopy. Conclusion: This therapeutic strategy for treating flaccidity is a comprehensive approach that improves the signs of flaccidity by acting on different skin planes and cellular targets. Peels are recommended to stimulate skin regeneration, mesotherapy to administer active ingredients for cellular biostimulation and cross-linked HA fillers to restore facial volume. Ex vivo studies have shown that peptides act at cellular and tissue levels, improving fibroblast function and stimulating the synthesis of ECM proteins, resulting in improved skin quality when tested clinically.